FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasiiiigtoii,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* LEONARD JOHN M.																	ationship of Reporting (all applicable) Director		10% Owne		ner	
	`	ERAPEUTICS,	(Middle) INC.		07/	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2020										X	below)	Officer (give title below) Other (specify below) President and CEO				
(Street) CAMBR (City)			02139 (Zip)		- 4. lí	4. If Amendment, Date of Original Filed (Month/Day/Year)										3. Indi _ine) X	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3)			n-Derivative S 2. Transaction Date (Month/Day/Year)		ar) if	2A. Deemed Execution Date,		3. Tr	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				r	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Co	de \	/	Amount		(A) or (D)	Pric	e		nsaction(s) str. 3 and 4)			Instr. 4)	
Common Stock		07/01	07/01/2020				1	M		5,000)	A	\$6	.83	472	472,352		D				
Common Stock		07/01	01/2020				S	(1)		5,000)	D	\$21.83		467,352			D				
Common Stock																58,415				By Γrust ⁽²⁾		
		Т	able II -									sed of onverti					wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		Transaction Code (Instr.		of I		s. Date Exercisa Expiration Date Month/Day/Yea			Amo Secu Unde Deriv	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		D S (I	s. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Own Forn Direc or In (I) (Ir	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable		xpiration ate	Title		Amou or Numb of Share	er						
Stock Option (right to buy)	\$6.83	07/01/2020			М			5,000	(3)	02	2/02/2026		nmon ock	5,00	0	\$0.00	340,23	4	D		

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. Shares held by the John M. Leonard 2015 Irrevocable Trust.
- 3. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020.

Remarks:

/s/Jose Rivera Attorney-In-Fact 07/02/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.